title: Performance on a strategy set shifting task during adolescence in a genetic model of attention deficit/hyperactivity disorder: methylphenidate vs. atomoxetine treatments.
abstract: Research examining medication effects on set shifting in teens with attention deficit/hyperactivity disorder (ADHD) is lacking. An animal model of ADHD may be useful for exploring this gap. The spontaneously hypertensive rat (SHR) is a commonly used animal model of ADHD. SHR and two comparator strains, Wistar-Kyoto (WKY) and Wistar (WIS), were evaluated during adolescence in a strategy set shifting task under conditions of a 0s or 15s delay to reinforcer delivery. The task had three phases: initial discrimination, set shift and reversal learning. Under 0s delays, SHR performed as well as or better than WKY and WIS. Treatment with 0.3mg/kg/day atomoxetine had little effect, other than to modestly increase trials to criterion during set shifting in all strains. Under 15s delays, SHR had longer lever press reaction times, longer latencies to criterion and more trial omissions than WKY during set shifting and reversal learning. These deficits were not reduced systematically by 1.5mg/kg/day methylphenidate or 0.3mg/kg/day atomoxetine. Regarding learning in SHR, methylphenidate improved initial discrimination, whereas atomoxetine improved set shifting but disrupted initial discrimination. During reversal learning, both drugs were ineffective in SHR, and atomoxetine made reaction time and trial omissions greater in WKY. Overall, WIS performance differed from SHR or WKY, depending on phase. Collectively, a genetic model of ADHD in adolescent rats revealed that neither methylphenidate nor atomoxetine mitigated all deficits in SHR during the set shifting task. Thus, methylphenidate or atomoxetine monotherapy may not mitigate all set shift task-related deficits in teens with ADHD.
authors: Department of Psychology, Boston University, Boston, MA 02215, USA.
authors: Roxann C
authors: RC
authors: Harvey
authors: Chloe J
authors: CJ
authors: Jordan
authors: David H
authors: DH
authors: Tassin
authors: Kayla R
authors: KR
authors: Moody
authors: Linda P
authors: LP
authors: Dwoskin
authors: Kathleen M
authors: KM
authors: Kantak
mesh_terms: D018759:Adrenergic Uptake Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy / Q000235:genetics; D003216:Conditioning, Operant / Q000187:drug effects*; D018765:Dopamine Uptake Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D008774:Methylphenidate / Q000494:pharmacology* / Q000627:therapeutic use; D011437:Propylamines / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D012193:Reversal Learning / Q000187:drug effects*; D013045:Species Specificity; D013997:Time Factors
chemical_list: D018759:Adrenergic Uptake Inhibitors; D018765:Dopamine Uptake Inhibitors; D011437:Propylamines; D008774:Methylphenidate; D000069445:Atomoxetine Hydrochloride
references: Behav Brain Funct. 2012 Jan 26;8:5
references: 22277367
references: J Consult Clin Psychol. 1997 Feb;65(1):150-160
references: 9103744
references: Behav Brain Res. 2011 Jan 1;216(1):472-6
references: 20813138
references: Child Neuropsychol. 2008 Nov;14(6):483-503
references: 18982507
references: Behav Brain Res. 2008 Jun 26;190(1):85-96
references: 18359099
references: Physiol Behav. 2008 Jun 9;94(3):481-6
references: 18452958
references: Physiol Behav. 1993 Nov;54(5):903-7
references: 8248381
references: J Neurosci. 2006 Mar 1;26(9):2449-57
references: 16510723
references: Behav Brain Res. 2002 Mar 10;130(1-2):37-45
references: 11864716
references: Neuropharmacology. 2007 Mar;52(3):812-26
references: 17140608
references: Psychopharmacology (Berl). 2009 Jan;202(1-3):497-504
references: 18535818
references: Neurobiol Learn Mem. 2003 Jul;80(1):63-79
references: 12737935
references: Child Neuropsychol. 2006 Apr;12(2):125-40
references: 16754533
references: Adolescence. 2001 Winter;36(144):749-65
references: 11928880
references: Mol Neurobiol. 2009 Apr;39(2):73-80
references: 19199083
references: Neurosci Biobehav Rev. 2000 Jan;24(1):31-9
references: 10654658
references: J Child Adolesc Psychopharmacol. 2009 Oct;19(5):485-92
references: 19877972
references: Neuropsychopharmacology. 2006 Feb;31(2):297-309
references: 16012531
references: Psychopharmacology (Berl). 2012 Jan;219(2):285-301
references: 21809008
references: Behav Neurosci. 2008 Apr;122(2):340-57
references: 18410173
references: Cogn Affect Behav Neurosci. 2013 Mar;13(1):164-73
references: 23055093
references: J Child Psychol Psychiatry. 1992 Oct;33(7):1217-28
references: 1400703
references: Biol Psychiatry. 2006 Nov 15;60(10):1111-20
references: 16806100
references: Behav Brain Res. 2002 Nov 15;136(2):339-48
references: 12429395
references: Pharmacol Biochem Behav. 2010 Jan;94(3):374-9
references: 19818805
references: Atten Defic Hyperact Disord. 2011 Mar;3(1):1-12
references: 21432613
references: J Neurosci. 2000 Jun 1;20(11):4320-4
references: 10818167
references: Behav Brain Res. 2005 Jul 1;162(1):47-61
references: 15922066
references: Neuropsychology. 2011 Jul;25(4):427-441
references: 21463041
references: Neuropsychopharmacology. 2002 Nov;27(5):699-711
references: 12431845
references: Int J Neuropsychopharmacol. 2010 Mar;13(2):243-56
references: 19849892
references: Child Neuropsychol. 2010;16(2):145-61
references: 19821169
references: J Child Adolesc Psychopharmacol. 2006 Jun;16(3):365-70
references: 16768644
references: Neurobiol Learn Mem. 2008 May;89(4):567-73
references: 18054257
references: Biol Psychiatry. 2005 Jun 1;57(11):1263-72
references: 15949998
references: Behav Pharmacol. 2004 Sep;15(5-6):341-52
references: 15343057
references: Neurosci Biobehav Rev. 2003 Jan-Mar;27(1-2):3-18
references: 12732219
references: Neurosci Biobehav Rev. 2006;30(8):1225-45
references: 17161238
references: Brain Res. 2011 Jun 17;1396:45-53
references: 21570676
references: Neuropharmacology. 2009 Dec;57(7-8):653-64
references: 19733553
references: Behav Brain Funct. 2008 Jan 23;4:3
references: 18215285
references: Pharmacol Res. 2010 Dec;62(6):523-9
references: 20691787
references: Behav Neurosci. 2011 Jun;125(3):372-82
references: 21500882
references: Pharmacol Biochem Behav. 2008 Aug;90(2):184-97
references: 18456311
references: Neuropharmacology. 2012 Mar;62(3):1299-307
references: 21376064
references: Am J Psychiatry. 1998 May;155(5):693-5
references: 9585725
references: J Child Adolesc Psychopharmacol. 2011 Oct;21(5):433-44
references: 22040189
references: J Neurosci. 2002 Aug 15;22(16):7264-71
references: 12177221
references: Cereb Cortex. 2001 Nov;11(11):1015-26
references: 11590111
references: J Pharmacol Exp Ther. 1987 Apr;241(1):152-8
references: 3572779
references: Behav Brain Funct. 2012 Feb 28;8(1):10
references: 22369105
references: Dialogues Clin Neurosci. 2002 Dec;4(4):444-8
references: 22034444
references: Behav Neural Biol. 1990 Jan;53(1):88-102
references: 2302145
references: Biol Psychiatry. 2012 Mar 1;71(5):467-73
references: 21890109
references: Behav Brain Res. 2006 Dec 15;175(2):337-42
references: 17034874
references: Brain Res. 1995 Apr 10;676(2):343-51
references: 7614004
references: Behav Brain Res. 2005 Feb 28;157(2):323-30
references: 15639183
references: J Child Psychol Psychiatry. 2006 May;47(5):457-71
references: 16671929
references: Pharmacol Biochem Behav. 2006 Mar;83(3):380-90
references: 16580713
references: Neurobiol Learn Mem. 2005 Mar;83(2):125-33
references: 15721796
references: Behav Neurosci. 2003 Aug;117(4):728-37
references: 12931958
references: Behav Neural Biol. 1992 Sep;58(2):103-12
references: 1360797
references: Biol Psychiatry. 2011 Jun 15;69(12):1192-203
references: 21047621
references: Behav Brain Res. 2007 May 16;179(2):219-28
references: 17337305
references: J Child Psychol Psychiatry. 2004 Feb;45(2):293-305
references: 14982243
references: Neuropsychopharmacology. 2012 Nov;37(12):2566-79
references: 22805599
references: Dev Psychobiol. 2011 May;53(4):391-401
references: 21365641
references: J Child Adolesc Psychopharmacol. 2004 Spring;14(1):129-36
references: 15142400
references: Drug Metab Dispos. 2003 Jan;31(1):88-97
references: 12485957
references: Child Psychiatry Hum Dev. 2011 Jun;42(3):257-69
references: 21165694
references: Psychol Med. 1999 May;29(3):527-38
references: 10405075
references: Eur J Pharmacol. 2012 Mar 15;679(1-3):60-7
references: 22306242
references: Neuropsychopharmacology. 2011 Mar;36(4):837-47
references: 21150910
references: Eur J Pharmacol. 1984 Sep 17;104(3-4):277-86
references: 6499924
references: Pediatrics. 1996 Aug;98(2 Pt 1):301-4
references: 8692637
references: J Abnorm Child Psychol. 2001 Dec;29(6):541-56
references: 11761287
references: Dev Med Child Neurol. 2011 Sep;53(9):843-849
references: 21585365
references: Curr Top Behav Neurosci. 2012;9:361-90
references: 21487953
references: Cortex. 2012 Feb;48(2):194-215
references: 21575934
references: Biol Psychiatry. 2007 Nov 1;62(9):977-84
references: 17644072
references: J Neurosci. 1999 Jun 1;19(11):4585-94
references: 10341256